Navigation Links
Avicena to Present at 4th Annual BIO InvestorForum Conference
Date:10/8/2007

Expansion of Drug Pipeline and Advancement of Clinical Programs

PALO ALTO, Calif., Oct. 8 /PRNewswire-FirstCall/ -- Avicena Group, Inc. (OTC Bulletin Board: AVGO), a late-stage biotechnology company that develops central nervous system therapeutics for neurodegenerative disorders, announced today that it will be a presenting company at the 4th Annual BIO InvestorForum Conference to be held October 9-11, 2007 at the Palace Hotel of San Francisco. The company's chief executive officer, Belinda Tsao-Nivaggioli, Ph.D., will present an overview of the company and its clinical programs, including an update on activities to build its drug pipeline and investigate new delivery vehicles to enhance the bioavailability of its lead drug candidates. Dr. Tsao-Nivaggioli will be presenting on Thursday, October 11 at 10:30 a.m. (EDT) in the Twin Peaks North room. For more information on this event please visit: http://www.investorforum.bio.org/.

To participate in a live audio and visual webcast of Dr. Tsao-Nivaggioli's presentation please log onto Avicena's corporate website at http://www.avicenagroup.com at least fifteen minutes prior to the start of the presentation to download any necessary materials. An archive of this event will be available in the investor relations section of the website for 30 days.

ABOUT AVICENA

Avicena Group, Inc. (OTC Bulletin Board: AVGO) is a Palo Alto, California based late stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases. The company's core technologies, supported by a robust IP portfolio, have broad applications in both pharmaceuticals and dermaceuticals. Avicena's pharmaceutical program centers on rare neurological disorders (orphan diseases). Near term, the company plans to initiate a confirmatory Phase III trial in ALS and a Phase III trial in Huntington's disease to accompany the ongoing NIH Phase III trail in Parkinson's disease. Avicena's science is well established and its products are safe and well tolerated. Unlike traditional biotechnology companies, Avicena's clinical programs are largely funded by government and non-profit organizations. Avicena presently derives revenue from the sale of proprietary dermaceutical ingredients to skin care manufacturers.

Contact:

The Ruth Group (on behalf of Avicena Group)

Sara Ephraim (investors)

(646) 536-7002

sephraim@theruthgroup.com

Janine McCargo / Jason Rando (media)

(646) 536-7033 / 7025

jmccargo@theruthgroup.com or jrando@theruthgroup.com


'/>"/>
SOURCE Avicena Group, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... Feb. 20, 2017 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ) announced ... CEO and Fabrice Orecchioni, the company,s COO, has been named President, ... the past four years, Fabrice has overseen the construction, start-up and ... and the management of the Mitsui JV.  Fabrice has also been ... China JV. ...
(Date:2/20/2017)... ... February 20, 2017 , ... Cancer diagnostics and pathology ... (Crosswalk), a unique precision medicine knowledge visualization and decision support platform. , ... diagnostic cockpit and is downloadable as an app for any mobile device and ...
(Date:2/20/2017)...  Former NFL players who had repeated head injuries may ... according to a preliminary study released today that will be ... in Boston , April 22 to 28, ... the muscles and nerves work together, like walking, kicking and ... ...
(Date:2/18/2017)... Kurzlehrgang mit Fokus auf Assay zum ... metaproteomische Analyse des Darm-Mikrobioms bei Säuglingen dar   ... Wie ... Peretz , Scientific Director bei ImmuneCarta, einen Kurzlehrgang zu ... intrazellulärer Zytokine bei adoptiven Zelltherapie-Studien im Rahmen der jährlich ...
Breaking Biology Technology:
(Date:2/3/2017)... 2017 A new independent identity strategy consultancy ... (IdSP) . Designed to fill a critical niche in ... founding partners Mark Crego and Janice ... in identity expertise that span federal governments, the 9/11 ... Crego-Kephart combined expertise has a common theme born from ...
(Date:2/2/2017)... -- Central to its deep commitment to honor the ... Prize Foundation today announced the laureates of the ... in their respective fields of Life Sciences and ... recognized with the 2017 Japan Prize for original ... the advancement of science and technology, but also ...
(Date:1/30/2017)... 30, 2017   Invitae Corporation (NYSE: ... information companies, today announced that it will report its ... 2017 guidance on Monday, February 13, 2017, and Invitae,s ... at 4:45 p.m. Eastern / 1:45 p.m. Pacific. ... briefly review financial results, guidance, and recent developments and ...
Breaking Biology News(10 mins):